Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.

Autor:	Walling D; CNS Network, Inc., Garden Grove, CA; davidwalling@cnstrial.com., Marder SR; Desert Pacific Mental Illness Research, Education, and Clinical Center UCLA Semel Institute for Neuroscience, Los Angeles, CA;, Kane J; Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY;, Fleischhacker WW; Department for Psychiatry and Psychotherapy, Division of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria;, Keefe RS; Schizophrenia Research Group, Psychiatry & Behavioral Sciences, Division of Medical Psychology, School of Medicine, Duke University, Durham, NC;, Hosford DA; Department of Clinical Development and Regulatory Affairs, Targacept Inc., Winston-Salem, NC., Dvergsten C; Department of Clinical Development and Regulatory Affairs, Targacept Inc., Winston-Salem, NC., Segreti AC; Department of Clinical Development and Regulatory Affairs, Targacept Inc., Winston-Salem, NC., Beaver JS; Department of Clinical Development and Regulatory Affairs, Targacept Inc., Winston-Salem, NC., Toler SM; Department of Clinical Development and Regulatory Affairs, Targacept Inc., Winston-Salem, NC., Jett JE; Department of Clinical Development and Regulatory Affairs, Targacept Inc., Winston-Salem, NC., Dunbar GC; Department of Clinical Development and Regulatory Affairs, Targacept Inc., Winston-Salem, NC.
Jazyk:	angličtina
Zdroj:	Schizophrenia bulletin [Schizophr Bull] 2016 Mar; Vol. 42 (2), pp. 335-43. Date of Electronic Publication: 2015 Jun 12.
DOI:	10.1093/schbul/sbv072
Abstrakt:	Objectives: This trial was conducted to test the effects of an alpha7 nicotinic receptor full agonist, TC-5619, on negative and cognitive symptoms in subjects with schizophrenia. Methods: In 64 sites in the United States, Russia, Ukraine, Hungary, Romania, and Serbia, 477 outpatients (18-65 years; male 62%; 55% tobacco users) with schizophrenia, treated with a new-generation antipsychotic, were randomized to 24 weeks of placebo (n = 235), TC-5619, 5mg (n = 121), or TC-5619, 50 mg (n = 121), administered orally once daily. The primary efficacy measure was the Scale for the Assessment of Negative Symptoms (SANS) composite score. Key secondary measures were the Cogstate Schizophrenia Battery (CSB) composite score and the University of California San Diego Performance-Based Skills Assessment-Brief Version (UPSA-B) total score. Secondary measures included: Positive and Negative Syndrome Scale in Schizophrenia (PANSS) total and subscale scores, SANS domain scores, CSB item scores, Clinical Global Impression-Global Improvement (CGI-I) score, CGI-Severity (CGI-S) score, and Subject Global Impression-Cognition (SGI-Cog) total score. Results: SANS score showed no statistical benefit for TC-5619 vs placebo at week 24 (5 mg, 2-tailed P = .159; 50 mg, P = .689). Likewise, no scores of CSB, UPSA-B, PANSS, CGI-I, CGI-S, or SGI-Cog favored TC-5619 (P > .05). Sporadic statistical benefit favoring TC-5619 in some of these outcome measures were observed in tobacco users, but these benefits did not show concordance by dose, country, gender, or other relevant measures. TC-5619 was generally well tolerated. Conclusion: These results do not support a benefit of TC-5619 for negative or cognitive symptoms in schizophrenia. (© The Author 2015. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu